Skip to main content

Advertisement

Table 3 Sensitivity analyses by random versus fixed effects for serious infection risk by comparison of significant estimates between random and fixed effects models

From: Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis

Comparison Random effects model Fixed effects model
Odds ratio (95 % CrI) Odds ratio (95 % CrI)
TAC vs. glucocorticoids 0.33 (0.12–0.88) 0.33 (0.13–0.82)
TAC vs. CYC 0.37 (0.15–0.87) 0.37 (0.16–0.82)
TAC vs. MMF 0.40 (0.18–0.81) 0.40 (0.20–0.78)
TAC vs. AZA 0.32 (0.12–0.81) 0.32 (0.13–0.77)
CYC LD vs. TAC 4.84 (1.48–17.64) 4.50 (1.43–14.50)
HD glucocorticoids vs. TAC 12.83 (1.53–119.90) 12.22 (1.58–105.70)
CYC HD vs. TAC 6.60 (2.25–20.50) 6.52 (2.38–18.95)
MMF-AZA vs. CYC LD 0.09 (0.01–0.76) 0.09 (0.01–0.74)
MMF-AZA vs. HD glucocorticoids 0.03 (0.00–0.56) 0.21 (0.02–1.79)
MMF-AZA vs. CYC HD 0.07 (0.01–0.54) 0.07 (0.01–0.47)
MMF-AZA vs. CYC-AZA 0.14 (0.02–0.71) 0.14 (0.02–0.65)
Residual deviance 72.49 74.9
Number of unconstrained data points 71 71
Deviance information criteria 325.646 325.51
  1. All odds ratios are statistically significant
  2. Odds ratios from either model are very similar to each other, denoting the robustness of the analyses, regardless of assumptions
  3. CYC cyclophosphamide, MMF mycophenolate mofetil, AZA azathioprine, TAC tacrolimus, HD high dose, LD low dose; when not specified, standard dose should be inferred